For the best experience of the website, please view this site in either Microsoft Edge, Google Chrome, Safari internet browsers rather than Internet Explorer.
Early findings from a clinical trial conducted by ATIC in Australia suggest that the immunotherapy MTX‑101 may calm the immune system and help preserve insulin production in people with type 1 diabetes.
